Further, the combination of avasimibe with anti-PD-1 antibody had a better efficacy than monotherapies in melanoma and LLC models, due to the drastic potentiation of effector functions in both PD-1hi and PD-1lo CD8+ T cells [226]. The gene discussed is CD8A; the disease is melanoma.